TCG Crossover GP I LLC 13D and 13G filings for KalVista Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-01 4:14 pm Sale | 2024-03-28 | 13D | KalVista Pharmaceuticals, Inc. KALV | TCG Crossover GP I LLC | 1,345,826 3.200% | -1,355,014 (-50.17%) | Filing |
| 2024-02-20 4:49 pm Sale | 2024-02-07 | 13D | KalVista Pharmaceuticals, Inc. KALV | TCG Crossover GP I LLC | 2,700,840 6.520% | -707,241 (-20.75%) | Filing |
| 2023-01-09 4:19 pm Purchase | 2022-12-28 | 13D | KalVista Pharmaceuticals, Inc. KALV | TCG Crossover GP I LLC | 3,408,081 9.900% | 3,408,081 (New Position) | Filing |